Lyell Immunopharma Inc. (NASDAQ: LYEL) Is Up 47.5% From Its 52-Week Low; YTD, It Is Down -12.14% – What To Do Now – Marketing Sentinel
Home  »  Science   »  Lyell Immunopharma Inc. (NASDAQ: LYEL) Is Up 47.5%...

Lyell Immunopharma Inc. (NASDAQ: LYEL) Is Up 47.5% From Its 52-Week Low; YTD, It Is Down -12.14% – What To Do Now

During the last session, Lyell Immunopharma Inc. (NASDAQ:LYEL)’s traded shares were 1.14 million. At the end of the trading day, the stock’s price was $6.80, reflecting an intraday gain of 6.92% or $0.44. The 52-week high for the LYEL share is $19.84, that puts it down -191.76 from that peak though still a striking 47.5% gain since the share price plummeted to a 52-week low of $3.57. The company’s market capitalization is $1.39B, and the average intraday trading volume over the past 10 days was 1.29 million shares, and the average trade volume was 848.23K shares over the past three months.

Lyell Immunopharma Inc. (LYEL) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. LYEL has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.3.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Lyell Immunopharma Inc. (NASDAQ:LYEL) trade information

Lyell Immunopharma Inc. (LYEL) registered a 6.92% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.92% in intraday trading to $6.80 this Thursday, 06/23/22, hitting a weekly high. The stock’s 5-day price performance is 43.76%, and it has moved by 58.88% in 30 days. Based on these gigs, the overall price performance for the year is -58.91%. The short interest in Lyell Immunopharma Inc. (NASDAQ:LYEL) is 15.64 million shares and it means that shorts have 23.36 day(s) to cover.

The consensus price target of analysts on Wall Street is $14.50, which implies an increase of 53.1% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12.00 and $16.00 respectively. As a result, LYEL is trading at a discount of -135.29% off the target high and -76.47% off the low.

Lyell Immunopharma Inc. (LYEL) estimates and forecasts

Statistics show that Lyell Immunopharma Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Lyell Immunopharma Inc. (LYEL) shares have gone down -8.11% during the last six months, with a year-to-date growth rate more than the industry average at 34.78% against 11.30. In the rating firms’ projections, revenue will increase 100.50% compared to the previous financial year.

Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to $1.07 million by the end of Jun 2022.

While earnings are projected to return -22.40% in 2022, the next five years will return -7.90% per annum.

LYEL Dividends

Lyell Immunopharma Inc. is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Lyell Immunopharma Inc. (NASDAQ:LYEL)’s Major holders

Lyell Immunopharma Inc. insiders own 15.88% of total outstanding shares while institutional holders control 59.71%, with the float percentage being 70.98%. MWG Management Ltd is the largest shareholder of the company, while 115 institutions own stock in it. As of Dec 30, 2021, the company held over 20.16 million shares (or 8.19% of all shares), a total value of $156.06 million in shares.

The next largest institutional holding, with 15.09 million shares, is of Apoletto Ltd.’s that is approximately 6.13% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $116.83 million.

Also, the Mutual Funds coming in first place with the largest holdings of Lyell Immunopharma Inc. (LYEL) shares are Price (T.Rowe) New Horizons Fund and Vanguard Total Stock Market Index Fund. Data provided on Dec 30, 2021 indicates that Price (T.Rowe) New Horizons Fund owns about 2.34 million shares. This amounts to just over 0.95 percent of the company’s overall shares, with a $18.08 million market value. The same data shows that the other fund manager holds slightly less at 0.69 million, or about 0.28% of the stock, which is worth about $5.3 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]